Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms

被引:43
|
作者
Regelmann, Warren E. [1 ]
Schechter, Michael S. [2 ,3 ]
Wagener, Jeffrey S. [4 ]
Morgan, Wayne J. [5 ]
Pasta, David J. [6 ]
Elkin, Eric P. [6 ]
Konstan, Michael W. [7 ,8 ]
机构
[1] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA
[2] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA
[3] Childrens Healthcare Atlanta, Atlanta, GA USA
[4] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO USA
[5] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA
[6] ICON Late Phase & Outcomes Res, San Francisco, CA USA
[7] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA
[8] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
关键词
cough; crackles; cystic fibrosis; sputum; weight decline; TOBRAMYCIN;
D O I
10.1002/ppul.22658
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background A standard definition of pulmonary exacerbation based on signs and symptoms would be useful for categorizing cystic fibrosis (CF) patients and as an outcome measure of therapy. The frequently used definition of treatment with intravenous antibiotics varies with practice patterns. One approach to this problem is to use large data sets which include a patient's signs and symptoms along with their clinician's decision to treat with antibiotics for the diagnosis of pulmonary exacerbation. Previous analysis of such a data set, the Epidemiologic Study of Cystic Fibrosis (ESCF), found that new crackles, increased cough, increased sputum, and weight decline were the four clinical characteristics most strongly influencing providers to treat young CF patients for a pulmonary exacerbation. The objectives of this study were to confirm that these four characteristics influence the decision to treat with antibiotics for a pulmonary exacerbation in young CF patients; to evaluate their implications for future nutritional status and lung function; and to assess the effect of antibiotic treatment on these characteristic signs and symptoms. Methods This was an observational, longitudinal cohort study of clinical care in children <6 years old cared for at sites participating in ESCF. Results Using data from children not included in the previous ESCF study, we confirmed that these four characteristics were significantly associated with the likelihood of physicians prescribing antibiotics to treat a pulmonary exacerbation. The number of these characteristics present at a single clinic visit before age 6 predicted hospitalization rate over the next year, the weight-for-age z-score, and the forced expiratory volume in 1sec (FEV1) percent predicted at age 7. Treatment with antibiotics was associated with a greater decrease in the proportion of children with crackles, cough, and Pseudomonas aeruginosa at a follow-up visit within 6 months. Conclusions New crackles, increased cough, increased sputum, and decline in weight percentile at a single clinic visit increase the risk of future malnutrition, hospitalization, and airflow obstruction in young children with CF. Treatment with antibiotics mitigates some of these signs and symptoms by the first follow-up visit. The presence of these four characteristic signs and symptoms is useful to define pulmonary exacerbations in young children with CF that respond to antibiotic treatment in the short-term and influence long-term prognosis. Pediatr Pulmonol. 2013; 48:649-657. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:649 / 657
页数:9
相关论文
共 50 条
  • [41] Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis
    Bouzek, Drake C.
    Ren, Clement L.
    Thompson, Misty
    Slaven, James E.
    Sanders, Don B.
    PEDIATRIC PULMONOLOGY, 2022, 57 (07) : 1709 - 1716
  • [42] Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations
    Farahbakhsh, Nazanin
    Tabatabaii, Seyed Ahmad
    Khanbabaee, Ghamartaj
    Sadr, Saeed
    Aghdam, Maryam Kazemi
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [43] Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations
    Seyed Ahmad Tabatabaii
    Ghamartaj Khanbabaee
    Saeed Sadr
    Nazanin Farahbakhsh
    Maryam Kazemi Aghdam
    Saran Lotfollahzadeh
    Amirhossein Hosseini
    Naghi Dara
    Mohammad Nanbakhsh
    Fatemeh Abdollah Gorji
    BMC Pulmonary Medicine, 20
  • [44] Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
    Emily DiMango
    Patricia Walker
    Claire Keating
    Maria Berdella
    Newell Robinson
    Elinor Langfelder-Schwind
    Diane Levy
    Xinhua Liu
    BMC Pulmonary Medicine, 14
  • [45] Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis
    Nazer, Dena
    Abdulhamid, Ibrahim
    Thomas, Ronald
    Pendleton, Sara
    PEDIATRIC PULMONOLOGY, 2006, 41 (08) : 744 - 749
  • [46] BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis
    Andre Schultz
    Charlie McLeod
    Scott Berry
    Julie Marsh
    Anne McKenzie
    Mitch Messer
    Jamie Wood
    Ben Saville
    Adam Jaffe
    Sarath Ranganathan
    Steve Stick
    Peter Wark
    Steve Webb
    Tom Snelling
    Trials, 24
  • [47] Effect of Treatment of Cystic Fibrosis Pulmonary Exacerbations on Systemic Inflammation
    Sagel, Scott D.
    Thompson, Valeria
    Chmiel, James F.
    Montgomery, Gregory S.
    Nasr, Samya Z.
    Perkett, Elizabeth
    Saavedra, Milene T.
    Slovis, Bonnie
    Anthony, Margaret M.
    Emmett, Peggy
    Heltshe, Sonya L.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (05) : 708 - 717
  • [48] Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations
    Davis, Chelsea S.
    Faino, Anna, V
    Onchiri, Frankline
    Gibson, Ronald L.
    Merjaneh, Lina
    Ramsey, Bonnie W.
    Rosenfeld, Margaret
    Cogen, Jonathan D.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2023, 20 (01) : 75 - 82
  • [49] Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
    Zemanick, Edith T.
    Harris, J. Kirk
    Wagner, Brandie D.
    Robertson, Charles E.
    Sagel, Scott D.
    Stevens, Mark J.
    Accurso, Frank J.
    Laguna, Theresa A.
    PLOS ONE, 2013, 8 (04):
  • [50] BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis
    Schultz, Andre
    McLeod, Charlie
    Berry, Scott
    Marsh, Julie
    McKenzie, Anne
    Messer, Mitch
    Wood, Jamie
    Saville, Ben
    Jaffe, Adam
    Ranganathan, Sarath
    Stick, Steve
    Wark, Peter
    Webb, Steve
    Snelling, Tom
    TRIALS, 2023, 24 (01)